Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs'

Ann Rheum Dis. 2021 Oct;80(10):e156. doi: 10.1136/annrheumdis-2021-220541. Epub 2021 Apr 27.

Authors

Serena Bugatti^{1

2}, Silvia Balduzzi³, Ludovico De Stefano^{3

2}, Antonio Manzo^{3

2}, Blerina Xoxi³, Laura Bogliolo³, Sara Monti^{3

2}, Paolo Delvino^{3

2}, Carlomaurizio Montecucco^{3

2}

Affiliations

¹ Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy serena.bugatti@unipv.it.
² Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
³ Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.

PMID: 33906858
DOI: 10.1136/annrheumdis-2021-220541

No abstract available

Keywords: Covid-19; biological therapy; vaccination.

Publication types

Letter
Comment

MeSH terms

COVID-19 Vaccines
COVID-19*
Humans
Muscular Diseases*
SARS-CoV-2
Vaccination

Substances

COVID-19 Vaccines